The Copay Fairness for Veterans Act (H.R.1644) amends title 38 to eliminate copayments by the Department of Veterans Affairs for medications that are or are part of preventive health services, and to bar copayments for preventive health services more broadly. It also expands the statutory definition of "preventive health services" to incorporate USPSTF A/B recommendations, ACIP immunization guidance, and specified women’s preventive services and contraceptives.
For compliance officers and VA program managers, the bill creates immediate coverage changes for VA pharmacy fills and outpatient services and embeds three external public-health standards into VA law. The practical effects will hinge on how VA operationalizes which drugs "are or are part of" a preventive service, how the agency reconciles evolving external guidance, and how Congress provides budgetary offsets for increased VA costs.
At a Glance
What It Does
The bill amends 38 U.S.C. §§ 1722A, 1710, and 1701 to (1) exclude medications tied to preventive services from copay requirements, (2) prohibit copays for preventive health services under VA hospital/medical care provisions, and (3) expand the statutory list of preventive services to include USPSTF A/B items, ACIP-recommended immunizations, and HRSA-listed women's preventive services plus FDA-approved contraceptives.
Who It Affects
Directly affects VA pharmacy operations, VISNs and medical centers billing systems, and enrolled veterans who obtain preventive medications or services through the VA health system — including women veterans using contraceptive care. It also affects VA budget planners and the Treasury as the ultimate funder of increased VA benefit costs.
Why It Matters
This bill converts several evidence-based public-health recommendations into mandatory no-copay benefits inside VA law, changing benefit design and pharmacy billing rules and potentially increasing VA demand and program costs. How VA implements the statutory phrases will determine compliance burdens and fiscal impacts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.R.1644 makes three tightly focused statutory changes. First, it adds a new exception to the copayment rule for medications "that are or are part of a preventive health service," meaning veterans would not pay pharmacy copays when the medicine is used within a preventive care context as defined by VA law.
Second, it prevents the VA from charging copayments for preventive health services under the hospital care and medical services statute, removing a dollar barrier to receiving preventive visits and procedures. Third, it amends the statutory definition of "preventive health services" to incorporate three external standards: USPSTF A/B recommendations, ACIP immunization recommendations, and HRSA preventive services for women as of December 30, 2022, plus FDA-approved contraceptives and related care.
On implementation, the key operational issue is classification: VA must identify which drug fills are "part of" a preventive service. That will require changes to pharmacy claims logic, clinical documentation expectations (for example, linking a prescription to a preventive visit or code), and possibly new coding or modifiers so pharmacists and billing staff can exempt copays consistently.
The agency will also need to reconcile the static reference to HRSA guidelines (a specific date) with the dynamic nature of clinical guidance from USPSTF and ACIP, which change over time.Budget and program management are the other practical considerations. Eliminating copays for an expanded set of services and medicines will increase VA outlays and may shift utilization patterns toward more preventive visits and pharmacy fills.
VA will need to project cost impacts, adjust internal budgets or seek appropriations, and update policy and training materials to prevent billing errors and fraud, such as medications dispensed for treatment being claimed as preventive.
The Five Things You Need to Know
The bill amends 38 U.S.C. §1722A(a)(3) to add an explicit copay exemption for "medication that is or is part of a preventive health service.", It inserts a new paragraph into 38 U.S.C. §1710(f) prohibiting VA from charging veterans copayments for preventive health services under that subsection.
The statutory definition of "preventive health services" in 38 U.S.C. §1701(9) would be expanded to include USPSTF-recommended items with an A or B grade.
The bill incorporates ACIP immunization recommendations and a fixed citation to HRSA preventive services for women as of December 30, 2022, plus all FDA-approved contraceptives and related care.
The text does not include an explicit effective date or transition rules, leaving operational timing and systems changes to VA guidance and potential appropriations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act's name: the "Copay Fairness for Veterans Act." This is a formal statutory caption only; it does not affect substance but is useful for references in implementing guidance and appropriations documents.
Exempt VA pharmacy copays for preventive medications
Adds subparagraph (E) to §1722A(a)(3) so that medications that "are or are part of a preventive health service" are exempt from VA medication copayments. Practically, this requires VA to determine and document when a prescription falls within that preventive category and to alter pharmacy claims processing so copays are waived at point-of-sale. The provision is phrased broadly and will likely prompt VA to issue implementing rules or internal policy clarifying when a medication qualifies (for example, a statin for primary prevention vs a statin for secondary prevention).
Bar copays for preventive health services under hospital and medical care authority
Inserts a new paragraph into §1710(f) and expands the list in §1710(g)(3) to include preventive health services, making veterans not liable for copayments tied to those services. This changes outpatient and inpatient billing rules and removes a previously available cost-sharing tool for some VA care. VA’s billing manuals and electronic health record billing flags will need updates so that preventive encounters and associated procedures are captured as non-billable to veterans.
Broaden the statutory definition of 'preventive health services'
Expands the definition by adding three new subparagraphs: (L) USPSTF A/B recommendations; (M) ACIP immunization recommendations; and (N) specified women's preventive services from HRSA as of December 30, 2022, plus FDA-approved contraceptives and related services. By tying the statutory baseline to external public-health authorities, the bill forces VA coverage decisions to track those organizations’ recommendations, though the HRSA reference is fixed to a specific date rather than dynamic. This will simplify adjudication when guidance aligns, but it creates questions when the external guidance changes or conflicts.
This bill is one of many.
Codify tracks hundreds of bills on Veterans across all five countries.
Explore Veterans in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Enrolled veterans who seek preventive care: They will face lower out-of-pocket costs for preventive visits and for medications prescribed as part of prevention, improving financial access to vaccines, screenings, contraceptives, and USPSTF-recommended interventions.
- Women veterans seeking contraceptive and routine preventive services: The statute explicitly incorporates HRSA women’s preventive services and FDA-approved contraceptives, expanding no-copay access to contraceptive counseling, methods, and related care.
- VA pharmacy patients using preventive medications (e.g., vaccines, statins used for primary prevention, contraceptives): Pharmacy copay collection will decline for qualifying fills, reducing point-of-sale barriers and potentially increasing adherence to preventive regimens.
Who Bears the Cost
- Department of Veterans Affairs (VA) operating budgets and VISNs: The VA will absorb higher service and medication costs and may need to reallocate funds or request additional appropriations to cover increased utilization and lost copay revenue.
- Congress and Treasury (federal finances): Eliminating copays increases federal outlays for VA care; absent offsetting savings, that cost ultimately accrues to taxpayers and competing budget priorities.
- VA billing and IT teams, plus community care billing partners: These groups must implement new coding logic, train staff, and modify claims systems to identify preventive services and related medicines accurately, creating short-term implementation costs and administrative burden.
- Non-VA community providers participating in VA Community Care: They will need to follow new billing rules when a service is considered preventive under VA’s expanded statutory definition, potentially altering reimbursements and documentation requirements.
Key Issues
The Core Tension
The central dilemma is between expanding access to evidence-based preventive care by removing financial barriers and the need for clear, administrable definitions and fiscal discipline: strengthening prevention promises clinical and population benefits but demands precise operational rules and funding to prevent inconsistent coverage, administrative strain, and budgetary strain on VA.
The bill fixes the scope of no-copay benefits by importing external public-health standards, but it leaves significant operational questions unanswered. Foremost is the open-ended phrase "medication that is or is part of a preventive health service," which requires VA to create clinical and claims definitions linking prescriptions to preventive intents; absent clear coding rules, VA risks inconsistent application across facilities and inadvertent denials or overpayments.
The statute’s reliance on USPSTF and ACIP is sensible from an evidence standpoint, but the HRSA women’s services reference is tied to a specific date (December 30, 2022). That static reference may freeze coverage for some services at an earlier standard or require separate statutory updates when HRSA guidance evolves.
Fiscal and program-management trade-offs are also unresolved. Removing copays typically increases utilization; if VA lacks offsetting savings from prevented downstream care or additional appropriations, the agency will need to prioritize services, slow rollouts, or absorb costs within existing budgets.
The bill likewise does not supply implementation timing or transitional billing rules, so pharmacies, clinicians, and community partners will face a patchwork period while VA issues guidance. Finally, converting evidence-based recommendations into mandatory statutory entitlements raises edge-case questions — for example, medications used for both preventive and therapeutic purposes, or vaccines recommended for some populations but not others — that will require careful policy design to avoid both under-coverage and fraud vulnerabilities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.